Document is current
Any future updates will be listed below
-
Authors
Park, Anthony K https://orcid.org/0000-0001-7692-8874
Monroy, Isabel
Ren, Yuwei
Lu, Cathy https://orcid.org/0009-0007-0112-4477
Chaurasiya, Shyambabu
Valencia, Hannah
Lent-Koop, Jackson
Cook, Colin
Kang, Seonah
Lopez, Lupita
Murad, John P
Yamaguchi, Yukiko
Urak, Ryan https://orcid.org/0000-0001-5289-5000
Chang, Wen-Chung
Shah, Monil
Chong, Leslie Mi Ok
Fong, Yuman
Forman, Stephen J
Wang, Xiuli https://orcid.org/0000-0001-5964-4327
Priceman, Saul J https://orcid.org/0000-0002-8136-2112
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct06063317 at ClinicalTrials.govDocuments that mention this clinical trial
Combination therapy with the oncolytic virus CF33-CD19 and blinatumomab for the treatment of advanced solid tumors.
https://doi.org/10.1200/jco.2024.42.16_suppl.tps2687
Universal off-the-shelf combination immunotherapy using oncolytic viruses to redirect T cell engagers to target solid tumors
https://doi.org/10.1136/jitc-2024-011051
-
Funding
Funding for this research was provided by:
Imugene Limited
Division of Cancer Prevention, National Cancer Institute (P30CA033572)
- License Information
